Work-up for Cutaneous Vasculitis
The work-up for cutaneous vasculitis requires skin biopsy for histopathologic confirmation, ANCA testing (both immunofluorescence and ELISA), structured clinical assessment with urinalysis, and basic laboratory tests to distinguish skin-limited disease from systemic vasculitis and identify underlying triggers. 1
Diagnostic Approach
Essential Initial Steps
Obtain a skin biopsy extending to the subcutis from the most tender, reddish, or purpuric lesional skin 1. This is strongly supportive of vasculitis diagnosis (Level of Evidence 3, Grade C). Serial sections are often required to identify the main vasculitic lesion 2. The depth of biopsy is critical—superficial biopsies miss deeper vessel involvement that changes diagnosis and prognosis.
Perform direct immunofluorescence on a separate biopsy specimen 2. This distinguishes IgA-associated vasculitis (Henoch-Schönlein purpura) from IgG-/IgM-associated vasculitis, which has significant prognostic implications.
Laboratory Evaluation
ANCA testing (both indirect immunofluorescence and ELISA) should be performed in the appropriate clinical context (Level of Evidence 1A, Grade A) 1. This is the highest-quality recommendation from the EULAR guidelines for identifying ANCA-associated vasculitis.
Conduct structured clinical assessment with urinalysis and basic laboratory tests (Level of Evidence 3, Grade C) 1. The urinalysis is particularly critical—persistent unexplained hematuria on urine microscopy that is not due to glomerulonephritis requires immediate urology consultation, especially in patients with prior cyclophosphamide exposure 1.
Distinguishing Skin-Limited from Systemic Disease
The clinical presentation guides the depth of investigation:
- Superficial small-vessel involvement (palpable purpura, infiltrated erythema) suggests dermal superficial vasculitis 2
- Deep vessel involvement (nodular erythema, livedo racemosa, deep ulcers, digital gangrene) indicates deep dermal or subcutaneous muscular-vessel vasculitis 2
Coexistence of pan-dermal small-vessel vasculitis and subcutaneous muscular-vessel vasculitis indicates connective tissue disease, ANCA-associated vasculitis, Behçet disease, or malignancy-associated vasculitis 2. This finding mandates comprehensive systemic evaluation.
Identifying Underlying Causes
Investigate three primary categories:
- Infections: Obtain appropriate cultures and serologies based on clinical suspicion 3
- Drug exposures: Detailed medication history including over-the-counter drugs and supplements 2
- Connective tissue diseases: Consider screening for systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis 4
Screen for hepatitis B and C in all patients, particularly when cryoglobulinemia is suspected 1. Hepatitis C-associated cryoglobulinemic vasculitis requires antiviral therapy (Level of Evidence 1B, Grade B).
Additional Testing Based on Clinical Context
- Serum immunoglobulin levels before considering IVIG therapy—patients with selective IgA deficiency risk anaphylaxis 1
- Cryoglobulins when clinical features suggest cryoglobulinemic vasculitis
- Complement levels (C3, C4) for immune complex-mediated disease
- Complete blood count, comprehensive metabolic panel, inflammatory markers (ESR, CRP)
Critical Pitfalls to Avoid
Do not rely on ANCA testing alone for treatment decisions—structured clinical assessment should inform changes in management (Level of Evidence 1b, Grade B) 5. ANCA positivity without clinical correlation leads to overtreatment.
Exclude pseudovasculitis (thrombotic disorders like antiphospholipid antibody syndrome) before initiating immunosuppression 2. These conditions mimic vasculitis but require anticoagulation, not immunosuppression.
Avoid superficial punch biopsies—they miss deeper vessel involvement and lead to misdiagnosis 2. The biopsy must extend to subcutis.
Referral Considerations
Patients with primary small and medium vessel vasculitis should be managed in collaboration with or at centers of expertise (Level of Evidence 3, Grade D) 1. This is particularly important for:
- Systemic manifestations requiring aggressive immunosuppression
- Refractory disease not responding to standard therapy
- Diagnostic uncertainty requiring multidisciplinary evaluation
The 2024 EULAR update reinforces that AAV are rare, heterogeneous, and potentially life-threatening diseases requiring multidisciplinary management by centers with specific vasculitis expertise 5.